FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...
Investor's Business Daily on MSN
Biotech stock Arcutis climbs into buy zone as FDA mulls expanded use for key skin treatment
Biotech stock Arcutis is in a buy zone and Wall Street is looking for the skin-diseases drugmaker to expand the use of its ...
Arcutis Biotherapeutics (ARQT) announced on Wednesday that the U.S. FDA accepted a supplemental New Drug Application for expanding the label of its Zoryve 0.05% cream for infants with atopic ...
(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the U.S. Food and Drug Administration (FDA) has ...
Arcutis Biotherapeutics said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its Zoryve topical treatment for infants with atopic dermatitis, the most ...
Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing innovations in immuno-dermatology, announced the U.S. Food and Drug Administration has approved the ...
Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In the INTEGUMENT-INFANT trial, 34.4% of patients achieved vIGA-AD success and 58.3% reached EASI-75 at week 4.
The FDA approved Zoryve cream 0.3% for the treatment of plaque psoriasis in children as young as 2 years, Arcutis announced ...
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results